Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06956235 · ClinicalTrials.gov registry record · Phase 2

Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)

A Phase 2 study of Hidradenitis Suppurativa, sponsored by Merck Sharp & Dohme.

Active
Registry status
Phase 2
Development phase
147
Enrollment target
20
Study locations

NCT06956235 is a Phase 2 study of Hidradenitis Suppurativa that is active but no longer recruiting, run by Merck Sharp & Dohme. The registered enrollment target is 147 participants, below the 595-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (75% lower). The trial reports 20 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06956235, a Phase 2 study of Hidradenitis Suppurativa, is active but no longer recruiting, sponsored by Merck Sharp & Dohme.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
147 participants
Enrollment target
20
Study locations

Study Summary

This is a phase 2b randomized, double-blind, placebo-controlled study of the safety and efficacy of tulisokibart in participants with moderate to severe hidradenitis suppurativa. The primary hypothesis is that at least 1 dose of tulisokibart is superior to placebo with respect to the proportion of participants achieving a 50% reduction in Hidradenitis Suppurativa Clinical Response (HiSCR50) at Week 16 (ie, at end of double-blind treatment).

Conditions Studied

Hidradenitis Suppurativa

Interventions

  • DRUG Placebo
  • DRUG Tulisokibart

Study Locations (20)

Texas

  • Arlington Center for Dermatology ( Site 0045) - Arlington
  • Texas Dermatology Research Center ( Site 0019) - Dallas
  • Reveal Research Institute ( Site 0018) - Frisco
  • Progressive Clinical Research ( Site 0020) - San Antonio

California

  • Northridge Clinical Trials ( Site 0004) - Northridge
  • Integrative Skin Science and Research ( Site 0015) - Sacramento

Ohio

  • University Hospitals Cleveland Medical Center ( Site 0046) - Cleveland
  • Wright State Physicians Health Center ( Site 0041) - Fairborn

Alabama

  • Cahaba Dermatology & Skin Health Center ( Site 0012) - Birmingham

Arizona

  • Medical Dermatology Specialists ( Site 0027) - Phoenix

Arkansas

  • Northwest Arkansas Clinical Trials Center, PLLC ( Site 0049) - Rogers

Florida

  • Olympian Clinical Research ( Site 0010) - Tampa

Georgia

  • Skin Care Physicians of Georgia ( Site 0033) - Macon

Trial Details

FieldValue
Enrollment Target 147 participants
Start Date 2025-06-09
Est. Completion 2029-01-22
Phase Phase 2

Sponsor

Merck Sharp & Dohme

558 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06956235

The ClinicalTrials.gov registry entry for NCT06956235 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 147 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 595-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (75% lower). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hidradenitis Suppurativa appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06956235 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Texas, California, Ohio.

Frequently Asked Questions

What is clinical trial NCT06956235 about?

NCT06956235 is a clinical study titled "Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)". This is a phase 2b randomized, double-blind, placebo-controlled study of the safety and efficacy of tulisokibart in participants with moderate to severe hidradenitis suppurativa. The primary hypothesis is that at least 1 dose of tulisokibart is superior to placebo with respect to the proportion of p...

What is the current status of trial NCT06956235?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 147 participants. The study started on 2025-06-09. Estimated completion is 2029-01-22.

What conditions does trial NCT06956235 study?

This clinical trial studies the following conditions: Hidradenitis Suppurativa.

What interventions are being tested in trial NCT06956235?

The interventions under investigation include: Placebo (DRUG), Tulisokibart (DRUG).

Who is sponsoring clinical trial NCT06956235?

This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06956235 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hidradenitis Suppurativa

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hidradenitis Suppurativa

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.